ΔN-ASPP2, a novel isoform of the ASPP2 tumor suppressor, promotes cellular survival

Kathryn Van Hook1, Zhiping Wang1, Dexi Chen2

  • 1Department of Medicine, Division of Hematology and Medical Oncology and the Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.

Insights

A newly discovered ASPP2 protein isoform, ΔN-ASPP2, promotes cancer progression by suppressing tumor suppressor p53 activity and increasing resistance to DNA damage, contrasting with the known tumor-suppressing ASPP2 protein.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • The tumor suppressor ASPP2 (Apoptosis-Stimulating Protein of p53) plays a crucial role in cancer by promoting p53-dependent apoptosis.
  • Understanding the regulation of ASPP2 is vital for cancer therapy.

Purpose of the Study:

  • To characterize a novel ASPP2 isoform, ΔN-ASPP2, and elucidate its role in cancer progression and the ASPP2-p53 axis.
  • To investigate the expression patterns of ΔN-ASPP2 and ASPP2 in human breast tumors.

Main Methods:

  • Identification and characterization of the ΔN-ASPP2 isoform.
  • Assays to evaluate the impact of ΔN-ASPP2 on p53 target gene transactivation and expression.
  • Cell cycle progression and apoptosis assays under genotoxic stress.
  • Quantitative analysis of ASPP2 and ΔN-ASPP2 expression in breast tumor tissues.

Main Results:

  • A new isoform, ΔN-ASPP2, was identified, lacking the N-terminal 254 amino acids of ASPP2.
  • ΔN-ASPP2 suppresses p53-mediated transactivation, promoter binding, and gene expression following DNA damage.
  • ΔN-ASPP2 enhances cell cycle progression and confers resistance to genotoxic stress-induced apoptosis and growth inhibition.
  • ΔN-ASPP2 expression is elevated in human breast tumors, while full-length ASPP2 is suppressed.

Conclusions:

  • The ΔN-ASPP2 isoform acts as a functional antagonist to ASPP2, promoting cell cycle progression and survival under stress.
  • Increased ΔN-ASPP2 expression in breast tumors suggests its contribution to tumorigenesis by counteracting ASPP2's tumor-suppressive functions.
  • This discovery reveals a new regulatory mechanism within the ASPP2-p53 pathway with potential implications for cancer diagnostics and therapeutics.

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.5K